Drug
Istradefylline clinical trials
Also written KW-6002 and Nourianz.
- studies test it
- 25
- open now
- 2
- in phase 3
- 11
- first study started
- 2000
Keep track of what changes. Save the istradefylline studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
24 studies that test it; most in 2005 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 3 |
| 2004 | 4 |
| 2005 | 6 |
| 2007 | 1 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 12
- Phase 3
- 11
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 6
Kyowa Kirin Co., Ltd. (10) · Kyowa Kirin, Inc. (9) · University of Florida (2) · Georgetown University (1) · University of Chicago (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Randy Trumbower, PT, PhD (1)
Studies
Open first, then newest update. How each study uses istradefylline is read from its arms, and is right about nine times in ten.
Testing it · 25
- Enhancing Rehabilitation in Aging Study (ERAS)Not yet recruitingPhase 1/2University of FloridaNCT07704385Written as Istradefylline 20 mg
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord InjuryNot yet recruitingPhase 1/2Randy Trumbower, PT, PhDNCT05217498Written as Istradefylline
- Adenosine 2A Receptor Antagonism and AIH in ALSActive, not recruitingPhase 1/2University of FloridaNCT05377424Written as Consume 20mg of istradefylline
- Istradefylline Effect Protocol on Parkinson's Disease TremorCompletedPhase 4Georgetown UniversityNCT05885360Written as Istradefylline Pill
- An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001TerminatedPhase 3Kyowa Kirin, Inc.NCT00199381Written as Istradefylline
- Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedPhase 3Kyowa Kirin Co., Ltd.NCT02610231Written as Istradefylline 20 mg or 40 mg
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaCompletedPhase 3Kyowa Kirin, Inc.NCT00199420Written as Istradefylline (KW-6002)
- A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedPhase 3Kyowa Kirin Co., Ltd.NCT01968031Written as Istradefylline 40 mg
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaCompletedPhase 2Kyowa Kirin, Inc.NCT00456794Written as Istradefylline (KW-6002)
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseCompletedPhase 3Kyowa Kirin Co., Ltd.NCT00199394Written as Istradefylline (KW-6002)
- Study of Istradefylline (KW-6002) for the Treatment of Restless Legs SyndromeCompletedPhase 2Kyowa Kirin, Inc.NCT00199446Written as Istradefylline (KW-6002)
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaCompletedPhase 2Kyowa Kirin, Inc.NCT00456586Written as KW-6002 (istradefylline)
- An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018CompletedPhase 3Kyowa Kirin, Inc.NCT00199368Written as Istradefylline ( KW-6002)
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedPhase 3Kyowa Kirin, Inc.NCT00199407Written as Istradefylline (KW-6002)
- Effect of Mild Hepatic Impairment on the Pharmacokinetics of IstradefyllineCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02256033Written as Istradefylline
- A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyCompletedPhase 2/3Kyowa Kirin, Inc.NCT00955045Written as istradefylline
- A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsCompletedPhase 2Kyowa Kirin, Inc.NCT00199433Written as Istradefylline (KW-6002)
- A Study to Evaluate Abuse Potential of IstradefyllineCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02609477Written as Istradefylline
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedPhase 2Kyowa Kirin Co., Ltd.NCT00199355Written as Istradefylline (KW-6002)
- Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on LevodopaCompletedPhase 3University of ChicagoNCT00203957Written as Istradefylline
See all 25 studies that test istradefylline →
Given in every arm · 1 — istradefylline is usual care beside what is tested
Codes
What other systems call istradefylline · ClinicalTrials.gg INT004063
- MeSH (NLM) C111599istradefyllineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2GZ0LIK7T4ISTRADEFYLLINEConfirmed FDA, NLM, Wikidata
- RxNorm 2199015One source FDA
- Wikidata Q905783istradefyllineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73268IstradefyllineOne source FDA
- DrugBank DB11757One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C111599 | istradefylline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2GZ0LIK7T4 | ISTRADEFYLLINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2199015 | — | One source FDA |
| Wikidata | Q905783 | istradefylline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73268 | Istradefylline | One source FDA |
| DrugBank | DB11757 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.